A few more catalysts coming. Especially now that UF is back to school The Company has expanded our R&D capabilities to include new lab space and instrumentation. These expanded capabilities will be used for both research and development activities associated with our FAIMS technology including product development, preclinical and clinical testing activities. The Company has also identified two Requests for Proposals from the NIH in areas of interest and expertise within the Company and has drafted and submitted two separate NIH proposals in Q1 of 2017. The review process will occur this summer with award announcements soon after for potential funding in Q4 of 2017. The Company has also initiated a new research agreement with the University of Florida in January of 2017 for basic research being conducted within the Chemistry Department at UF. The work being conducted will be feed into our FAIMS product development program during the course of the year.
News 
Market Data 
Discover 
AI
